Sequential targeting of PI3Kδ and LAG3 as an effective anti-cancer approach

Summary Emerging studies have demonstrated the potential of PI3Kδ blockade as an immunotherapy for solid tumours. In pre-clinical models, we recently demonstrated that anti-LAG3 immune checkpoint blockade vastly potentiated PI3Kδ-based immunotherapy, enabling successful tumour control in all treated...

Ausführliche Beschreibung

Gespeichert in:

Bibliographische Detailangaben
Veröffentlicht in:	British journal of cancer 2021-08, Vol.125 (4), p.467-469
Hauptverfasser:	Lauder, Sarah N., Vanhaesebroeck, Bart, Gallimore, Awen
Format:	Artikel
Sprache:	eng
Schlagworte:	631/250/251 631/250/580 631/67/580 Animals Antigens, CD - immunology Biomedical and Life Sciences Biomedicine Cancer Research Class I Phosphatidylinositol 3-Kinases - immunology Comment Drug Resistance Drug Resistance, Neoplasm - drug effects Drug Synergism Epidemiology Humans Immune checkpoint Immune Checkpoint Inhibitors - pharmacology Immune Checkpoint Inhibitors - therapeutic use Immunotherapy Life Sciences & Biomedicine Lymphocyte Activation Gene 3 Protein Mice Molecular Medicine Neoplasms - drug therapy Neoplasms - immunology Oncology Science & Technology Solid tumors Tumor Microenvironment Xenograft Model Antitumor Assays
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!

Beschreibung
Zusammenfassung:	Summary Emerging studies have demonstrated the potential of PI3Kδ blockade as an immunotherapy for solid tumours. In pre-clinical models, we recently demonstrated that anti-LAG3 immune checkpoint blockade vastly potentiated PI3Kδ-based immunotherapy, enabling successful tumour control in all treated mice.
ISSN:	0007-0920 1532-1827
DOI:	10.1038/s41416-021-01285-1